Introduction: Viral blips have been associated with larger reservoir size and slower decay. Earlier antiretroviral therapy (ART) initiation may decrease the risk of blips.
Methods: We analyzed participants from the U.S. Military HIV Natural History Study with an estimated HIV seroconversion date, viral suppression ≤400 copies/mL within 1 year after starting ART, and at least 3 HIV RNA measurements after suppression. A blip was HIV RNA 401-1000 copies/mL preceded and followed by HIV RNA ≤400 copies/mL without changing ART. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for factors potentially associated with the time from viral suppression to first blip.
Results: From 1996-2022, 1,413 participants on stable suppressive ART had a median age at HIV diagnosis of 29.2 years (interquartile range 24.9-35.4) and 1361 (96.3%) were males. Viral blips were observed in 88 (6.2%) participants, 68 (77.3%) of whom had a single blip. The overall incidence was 1.2 blips per 100 person-years (95% CI 0.9-1.4). In multivariable modeling, ART initiation within 24 months of estimated HIV acquisition was independently associated with decreased hazard of viral blips as compared to ART initiation after more than 24 months (0-6 months HR 0.29 [95% CI 0.18-0.48]; 6-12 months HR 0.43 [95% CI 0.31-0.59]; 12-24 months HR 0.46 [95% CI 0.35-0.60]).
Conclusions: Participants who initiated ART within two years of HIV acquisition had lower hazard of blips, potentially reflecting smaller reservoir size and suggesting reservoir plasticity that extends beyond the acute phase of HIV.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/cid/ciaf103 | DOI Listing |
Clin Infect Dis
March 2025
Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Introduction: Viral blips have been associated with larger reservoir size and slower decay. Earlier antiretroviral therapy (ART) initiation may decrease the risk of blips.
Methods: We analyzed participants from the U.
Nature
March 2025
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Broadly neutralizing antibodies (bNAbs) show potential to prevent human immunodeficiency virus (HIV-1) infection in humans. However, there are limited data on the antibody concentrations required to prevent infection. Clinical trials of bNAb prophylaxis have demonstrated partial efficacy, but the sampling frequency typically does not allow precise timing of infection events and concurrent antibody levels.
View Article and Find Full Text PDFHIV Med
February 2025
Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario "Agostino Gemelli", IRCCS, Rome, Italy.
Objectives: This study aimed to evaluate the HIV virological efficacy of two-drug regimens (2DR) with lamivudine (3TC) and dolutegravir (DTG) in people with HIV (PWH), classified by their hepatitis B virus (HBV) serological status. Specifically, it explored whether isolated anti-hepatitis B core (anti-HBc) positivity impacts virological outcomes.
Methods: A retrospective observational study was conducted at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, enrolling 606 virologically suppressed (HIV-RNA < 50 copies/mL) PWH who switched to a 2DR regimen with 3TC/DTG.
Front Immunol
November 2024
Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH, United States.
Background: Heightened levels of inflammatory markers are linked to increased morbidity/mortality in people with HIV (PWH) and often remain elevated after virologic suppression by antiretroviral therapy (ART). As new combinations of ART become available, an evaluation of their effects on immune activation and inflammation is warranted. Additionally, it remains unknown whether transient increases in viral load ("blips") during ART are associated with increases in inflammation.
View Article and Find Full Text PDFJ Acquir Immune Defic Syndr
March 2025
South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!